title: Feasibility Of Administering Adjuvant Chemotherapy Of Pemetrexed Followed By Pemetrexed/oxaliplatin Immediately Post-VATS In Patients With Completely Resected NSCLC.
abstract: Non-small cell lung cancer (NSCLC) accounts for the largest number of cancer deaths annually, worldwide. It seems reasonable to test a less toxic regimen also in early stages after complete (R0) resection of the tumor, where reduced toxicities might improve the feasibility of drug delivery, compliance and the convenience of treatment for the patient and hence perhaps improve survival. The main purpose of this phase II trial is to evaluate the clinical feasibility-in terms of patients without dose limiting toxicities or premature treatment withdrawal or death-of administering adjuvant chemotherapy of pemetrexed followed by pemetrexed/oxaliplatin immediately post-VATS (video-assisted thoracic surgery) in patients with completely resected NSCLC.
authors.affiliation: Department of Cardiothoracic Surgery, the First Affiliated Hospital of Guangzhou Medical College; Guangzhou Research Institute of Respiratory Disease & China State Key Laboratory of Respiratory Disease, Guangzhou, PR China.
authors.forename: Jianxing
authors.initials: J
authors.lastname: He
authors.forename: Wenlong
authors.initials: W
authors.lastname: Shao
authors.forename: Shuben
authors.initials: S
authors.lastname: Li
authors.forename: Manyin
authors.initials: M
authors.lastname: Chen
authors.forename: Hanzhang
authors.initials: H
authors.lastname: Chen
authors.forename: Jun
authors.initials: J
authors.lastname: Liu
authors.forename: Wei
authors.initials: W
authors.lastname: Wang
authors.forename: Yuan
authors.initials: Y
authors.lastname: Qiu
authors.forename: Daoyuan
authors.initials: D
authors.lastname: Wang